Dare Bioscience, Inc.
DARE Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$0.66
KIRA · Stoqly’s AI analyst, in plain words
- Dare Bioscience, Inc. had $1.0M of revenue in fiscal 2025, up 10,412.2% on the year before.
- Its operating margin was −1,315.5%, up 237,985.5 pts: of every 100 in sales, about −1,316 is left after running the business.
- Dare Bioscience, Inc. lost $13.4M in fiscal 2025.
- Free cash flow was −$10.3M in fiscal 2025, −997.0% of revenue.
Market cap
$9.9M
P/E
—
Revenue
$1.0M
Net income
−$13.4M
Free cash flow
−$10.3M
Operating margin
−1,315.5%
Dare Bioscience, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+10,412.2%
Yes. Sales grew 10,412.2% last year.
Does it make a profit?
−1,300.7%
No. It lost money last year.
Does profit turn into cash?
−997.0%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Dare Bioscience, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 26, 2026
- Legal name
- Dare Bioscience, Inc.
- CIK
- 0001401914
Dare Bioscience, Inc. · DARE
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.0M | $10.0M | $2.8M | $0.0M | $1.0M |
| Revenue growth | — | — | −71.9% | −99.7% | 10,412.2% |
| Gross margin | — | — | — | 100.0% | 71.3% |
| Operating margin | — | −313.9% | −1,101.9% | −239,301.0% | −1,315.5% |
| Net income | −$38.7M | −$30.9M | −$30.2M | −$4.1M | −$13.4M |
| Net margin | — | −309.5% | −1,074.2% | −41,363.3% | −1,300.7% |
| Diluted EPS | −$0.63 | −$0.37 | −$4.15 | −$0.48 | −$1.20 |
| Cash | |||||
| Cash from operations | −$28.8M | −$18.1M | −$38.9M | $5.5M | −$9.9M |
| Capital expenditure | $0.0M | $0.1M | $0.6M | $0.6M | $0.4M |
| Free cash flow | −$28.8M | −$18.2M | −$39.5M | $4.9M | −$10.3M |
| FCF margin | — | −181.5% | −1,406.3% | 50,006.1% | −997.0% |
| Share count change | 103.2% | 38.3% | −91.4% | 16.8% | 31.6% |
| Debt and strength | |||||
| Cash and short-term investments | $51.7M | $34.7M | $10.5M | $15.7M | $24.7M |
| Debt incl. finance leases | — | — | — | $0.0M | — |
| Shareholders' equity | $38.8M | $11.1M | −$5.0M | −$6.0M | $2.8M |
| Current ratio | 3.4x | 1.4x | 0.9x | 0.9x | 1.1x |
| Returns and quality | |||||
| Return on equity | −205.8% | −124.1% | −994.7% | — | — |
| Return on tangible equity | −99.8% | −278.5% | — | — | −471.4% |
| Piotroski F-score | — | 2 | 1 | 3 | 3 |
| Altman Z'' | −4.1 | −13.2 | −37.1 | −34.2 | −21.0 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Dare Bioscience, Inc. · DARE
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.66 a share, the company is worth $9.9M.
Source: SEC EDGAR XBRL filings (CIK 0001401914). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.